The Washington Post (8/11, Kornfield) reports that naloxone, “an affordable antidote for opioid overdoses, has become more difficult to obtain amid a fatal epidemic.” According to the Post, “after a manufacturing issue halted Pfizer’s production of the single-dose injectable naloxone in April, groups that distribute a significant amount of the lifesaving medicine say they are facing an unprecedented obstacle to reverse drug overdoses as they reach an all-time high.” What’s more, “organizers say the insufficient supply has been felt unequally across the” US. For its part, drugmaker “Pfizer, which offers naloxone at a discount to a national buyer’s club made up of harm prevention programs, said it may take until February before it can meet demand again.”
Related Links:
— “The Washington Post (requires login and subscription)